Search Results - "McCue, Peter"

Refine Results
  1. 1
  2. 2
  3. 3

    Comprehensive Immunohistochemical Study of Programmed Cell Death Ligand 1 (PD-L1): Analysis in 5536 Cases Revealed Consistent Expression in Trophoblastic Tumors by Inaguma, Shingo, Wang, Zengfeng, Lasota, Jerzy, Sarlomo-Rikala, Maarit, McCue, Peter A, Ikeda, Hiroshi, Miettinen, Markku

    Published in The American journal of surgical pathology (01-08-2016)
    “…Programmed cell death 1/programmed cell death ligand (PD-1/PD-Ls) axis is crucial for the modulation of immune responses and self-tolerance. Also, aberrant…”
    Get full text
    Journal Article
  4. 4
  5. 5

    Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets by Witkiewicz, Agnieszka K., McMillan, Elizabeth A., Balaji, Uthra, Baek, GuemHee, Lin, Wan-Chi, Mansour, John, Mollaee, Mehri, Wagner, Kay-Uwe, Koduru, Prasad, Yopp, Adam, Choti, Michael A., Yeo, Charles J., McCue, Peter, White, Michael A., Knudsen, Erik S.

    Published in Nature communications (09-04-2015)
    “…Pancreatic ductal adenocarcinoma (PDA) has a dismal prognosis and insights into both disease etiology and targeted intervention are needed. A total of 109…”
    Get full text
    Journal Article
  6. 6

    SALL4 Expression in Germ Cell and Non–Germ Cell Tumors: A Systematic Immunohistochemical Study of 3215 Cases by Miettinen, Markku, Wang, Zengfeng, McCue, Peter A., Sarlomo-Rikala, Maarit, Rys, Janusz, Biernat, Wojciech, Lasota, Jerzy, Lee, Yi-Shan

    Published in The American journal of surgical pathology (01-03-2014)
    “…The SALL4 transcription factor is associated with embryonic cell pluripotency and has been shown as a useful immunohistochemical marker for germ cell tumors…”
    Get full text
    Journal Article
  7. 7

    Transplant glomerulopathy by Filippone, Edward J, McCue, Peter A, Farber, John L

    Published in Modern pathology (01-02-2018)
    “…In the renal allograft, transplant glomerulopathy represents a morphologic lesion and not a specific diagnosis. The hallmark pathologic feature is glomerular…”
    Get full text
    Journal Article
  8. 8

    Immunologic and Metabolic Features of Pancreatic Ductal Adenocarcinoma Define Prognostic Subtypes of Disease by Hutcheson, Jack, Balaji, Uthra, Porembka, Matthew R, Wachsmann, Megan B, McCue, Peter A, Knudsen, Erik S, Witkiewicz, Agnieszka K

    Published in Clinical cancer research (15-07-2016)
    “…Pancreatic ductal adenocarcinoma (PDA) is associated with an immunosuppressive microenvironment that supports the growth of the malignancy as well as immune…”
    Get full text
    Journal Article
  9. 9

    Paracrine Effect of NRG1 and HGF Drives Resistance to MEK Inhibitors in Metastatic Uveal Melanoma by Cheng, Hanyin, Terai, Mizue, Kageyama, Ken, Ozaki, Shinji, McCue, Peter A, Sato, Takami, Aplin, Andrew E

    Published in Cancer research (Chicago, Ill.) (01-07-2015)
    “…Uveal melanoma patients with metastatic disease usually die within one year, emphasizing an urgent need to develop new treatment strategies for this cancer…”
    Get full text
    Journal Article
  10. 10

    microRNA 17/20 inhibits cellular invasion and tumor metastasis in breast cancer by heterotypic signaling by Yu, Zuoren, Willmarth, Nicole E, Zhou, Jie, Katiyar, Sanjay, Wang, Min, Liu, Yang, McCue, Peter A, Quong, Andrew A, Lisanti, Michael P, Pestell, Richard G

    “…microRNAs are thought to regulate tumor progression and invasion via direct interaction with target genes within cells. Here the microRNA17/20 cluster is shown…”
    Get full text
    Journal Article
  11. 11
  12. 12

    FOXD3 Regulates VISTA Expression in Melanoma by Rosenbaum, Sheera R., Knecht, Meghan, Mollaee, Mehri, Zhong, Zhijiu, Erkes, Dan A., McCue, Peter A., Chervoneva, Inna, Berger, Adam C., Lo, Jennifer A., Fisher, David E., Gershenwald, Jeffrey E., Davies, Michael A., Purwin, Timothy J., Aplin, Andrew E.

    Published in Cell reports (Cambridge) (14-01-2020)
    “…Immune checkpoint inhibitors have improved patient survival in melanoma, but the innate resistance of many patients necessitates the investigation of…”
    Get full text
    Journal Article
  13. 13
  14. 14

    Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017 by Giri, Veda N, Knudsen, Karen E, Kelly, William K, Abida, Wassim, Andriole, Gerald L, Bangma, Chris H, Bekelman, Justin E, Benson, Mitchell C, Blanco, Amie, Burnett, Arthur, Catalona, William J, Cooney, Kathleen A, Cooperberg, Matthew, Crawford, David E, Den, Robert B, Dicker, Adam P, Eggener, Scott, Fleshner, Neil, Freedman, Matthew L, Hamdy, Freddie C, Hoffman-Censits, Jean, Hurwitz, Mark D, Hyatt, Colette, Isaacs, William B, Kane, Christopher J, Kantoff, Philip, Karnes, R Jeffrey, Karsh, Lawrence I, Klein, Eric A, Lin, Daniel W, Loughlin, Kevin R, Lu-Yao, Grace, Malkowicz, S Bruce, Mann, Mark J, Mark, James R, McCue, Peter A, Miner, Martin M, Morgan, Todd, Moul, Judd W, Myers, Ronald E, Nielsen, Sarah M, Obeid, Elias, Pavlovich, Christian P, Peiper, Stephen C, Penson, David F, Petrylak, Daniel, Pettaway, Curtis A, Pilarski, Robert, Pinto, Peter A, Poage, Wendy, Raj, Ganesh V, Rebbeck, Timothy R, Robson, Mark E, Rosenberg, Matt T, Sandler, Howard, Sartor, Oliver, Schaeffer, Edward, Schwartz, Gordon F, Shahin, Mark S, Shore, Neal D, Shuch, Brian, Soule, Howard R, Tomlins, Scott A, Trabulsi, Edouard J, Uzzo, Robert, Vander Griend, Donald J, Walsh, Patrick C, Weil, Carol J, Wender, Richard, Gomella, Leonard G

    Published in Journal of clinical oncology (01-02-2018)
    “…Purpose Guidelines are limited for genetic testing for prostate cancer (PCA). The goal of this conference was to develop an expert consensus-driven working…”
    Get full text
    Journal Article
  15. 15

    Composite analysis of immunological and metabolic markers defines novel subtypes of triple negative breast cancer by Adams, Thomas A, Vail, Paris J, Ruiz, Amanda, Mollaee, Mehri, McCue, Peter A, Knudsen, Erik S, Witkiewicz, Agnieszka K

    Published in Modern pathology (01-02-2018)
    “…Cancer biology is influenced by the tumor microenvironment, which impacts disease prognosis and therapeutic interventions. The inter-relationship of…”
    Get full text
    Journal Article
  16. 16

    Sarcomatoid renal cell tumor harboring a novel BYSL::TFEB fusion with concurrent TFEB amplification by Lin, Ruihe, Flerova, Elizaveta, Wamsley, Christine E., McCue, Peter A., Lallas, Costas D., Jiang, Wei, Huang, Jialing, Wang, Zi‐Xuan, Li, Li

    Published in Genes chromosomes & cancer (01-06-2023)
    “…Transcription factor EB (TFEB)‐rearranged renal cell carcinoma (RCC) exhibits diverse gene fusion patterns and heterogeneous clinicopathologic features. Rare…”
    Get full text
    Journal Article
  17. 17

    A Cyclin D1/microRNA 17/20 Regulatory Feedback Loop in Control of Breast Cancer Cell Proliferation by Yu, Zuoren, Wang, Chenguang, Wang, Min, Li, Zhiping, Casimiro, Mathew C., Liu, Manran, Wu, Kongming, Whittle, James, Ju, Xiaoming, Hyslop, Terry, McCue, Peter, Pestell, Richard G.

    Published in The Journal of cell biology (11-08-2008)
    “…Decreased expression of specific microRNAs (miRNAs) occurs in human tumors, which suggests a function for miRNAs in tumor suppression. Herein, levels of the…”
    Get full text
    Journal Article
  18. 18
  19. 19

    MCT4 Defines a Glycolytic Subtype of Pancreatic Cancer with Poor Prognosis and Unique Metabolic Dependencies by Baek, GuemHee, Tse, Yan F., Hu, Zeping, Cox, Derek, Buboltz, Noah, McCue, Peter, Yeo, Charles J., White, Michael A., DeBerardinis, Ralph J., Knudsen, Erik S., Witkiewicz, Agnieszka K.

    Published in Cell reports (Cambridge) (24-12-2014)
    “…KRAS mutation, which occurs in ∼95% of pancreatic ductal adenocarcinoma (PDA), has been shown to program tumor metabolism. MCT4 is highly upregulated in a…”
    Get full text
    Journal Article
  20. 20

    ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma by Capparelli, Claudia, Purwin, Timothy J, Heilman, Shea A, Chervoneva, Inna, McCue, Peter A, Berger, Adam C, Davies, Michael A, Gershenwald, Jeffrey E, Krepler, Clemens, Aplin, Andrew E

    Published in Cancer research (Chicago, Ill.) (01-10-2018)
    “…MEK-ERK1/2 signaling is elevated in melanomas that are wild-type for both BRAF and NRAS (WT/WT), but patients are insensitive to MEK inhibitors…”
    Get full text
    Journal Article